ABBV vs PG: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Procter & Gamble Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
The Procter & Gamble Company · Consumer Defensive
$150.38
+10.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
PG has more upside to fair value
(+10.0%).
PG trades at a lower forward P/E
(21.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
PG |
| Current Price |
$261.07 |
$150.38 |
| Fair Value Estimate |
$264.30 |
$165.39 |
| Upside to Fair Value |
+1.2%
|
+10.0%
|
| Market Cap |
$461.3B |
$350.2B |
| Forward P/E |
128.0x
|
21.5x
|
| EV / EBITDA |
31.0x
|
15.1x
|
| Price / Sales |
7.3x
|
4.0x
|
| Price / FCF |
22.1x
|
23.3x
|
| Revenue Growth YoY |
+12.4%
|
+7.4%
|
| Gross Margin |
70.7%
|
50.3%
|
| Operating Margin |
27.6%
|
23.2%
|
| Return on Equity |
68.0%
|
31.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
4.29%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
The Procter & Gamble Company is a leading global consumer defensive company specializing in household and personal products with a strong portfolio across fabric care, baby and family care, beauty, health care, and grooming. The business quality is high, supported by a durable competitive moat from strong brands, consistent earnings growth, and prudent capital allocation emphasizing dividends and…
Accumulation Zones
| Metric |
ABBV |
PG |
| Zone Low |
$198.23 |
$124.04 |
| Zone High |
$224.66 |
$140.58 |
| In Buy Zone? |
No
|
No
|